Table 2.

Incremental Cost-Effectiveness Ratio and Differences in Payoffs When Comparing Each Hypothetical Panel With Standard of Care or the Next Most Effective Strategy

Measure	Panel 1	Panel 2	Panel 3	Panel 4
Compared with standard of care
Δ Life-years	0.023	0.143	0.151	0.161
Δ QALY	0.019	0.121	0.128	0.136
Δ Costs, $	2,753	4,527	4,656	5,329
Cost per life-year gained, $	122,316	31,623	30,813	33,020
Cost per QALY gained, $	144,235	37,467	36,508	39,112
Compared with next best strategy
Δ Life-years	0.023	0.121	0.008	0.010
Δ QALY	0.019	0.102	0.007	0.009
Δ Costs, $	2,753	1,774	129	672
Cost per life-year gained, $	122,316	14,703	16,227	65,539
Cost per QALY gained, $	144,235	17,436	19,242	77,319

NOTE. The baseline life-years gained, baseline QALYs, and baseline costs with standard of care are 0.167, 0.141, and $3,905, respectively. Delta (Δ) life-years, QALY, and costs are the difference of each panel compared with the next best strategy or the standard of care. Panel 1 contains only Lynch-associated genes; panel 2 includes Lynch-associated genes plus those associated with autosomal dominant conditions and high colorectal cancer penetrance; panel 3 includes the genes in panel 2 plus the ones associated with autosomal recessive conditions and high colorectal cancer penetrance; and panel 4 includes the genes in panel 3 plus those associated with autosomal dominant conditions with low penetrance of colorectal cancer.

Abbreviation: QALY, quality-adjusted life-year.